Apellis: 4 Marketing Applications for Pegcetacoplan for Geographic Atrophy Validated

 

• Applications are under review in Canada, Australia, the United Kingdom, and Switzerland
   
• Approval decisions expected in the first half of 2024

 Apellis Pharmaceuticals Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company has received validation of its marketing applications by regulatory authorities in Canada, Australia, the United Kingdom, and Switzerland for intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Decisions by local regulatory authorities in these countries are expected in the first half of 2024.

https://www.biospace.com/article/releases/apellis-announces-validation-of-four-marketing-applications-for-pegcetacoplan-for-geographic-atrophy/